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The aim of this investigation was to compare the clinical effects and pharmacokinet-
ics of lidocaine (one metabolite) and mepivacaine (two metabolites) in 2 groups of
15 patients undergoing axillary brachial plexus anaesthesia. The study had a
randomised design. The 30 patients were divided into 2 groups. The patients re-
ceived either lidocaine (600 mg = 2.561 mMol + 5 mg ml–1 adrenaline) or mepivacaine
(600 mg = 2.436 mMol + 5 mg ml–1 adrenaline), injected via the axilla near the brachial
plexus over a period of 30 s. Onset of surgical analgesia was defined as the period
from the end of the local anaesthetic injection to the loss of pinprick sensation in
the distribution of the ulnar, radial, and median nerve. Motor block was measured.
Onset of motor block was similar for both drugs. Lidocaine is eliminated
biexponentially with a t1/2a  of 9.95 ± 14.3 min and a t1/2b of 2.86 ± 1.55 h. Lidocaine is
metabolised into MEGX (tmax 2.31 ± 0.84 h; Cmax 0.32 ± 0.13 mg l–1; t1/2b 2.36 ± 2.35 h;
total body clearance was 67.9 ± 28.9 l h–1).
Mepivacaine is eliminated rapidly and monoexponentially with a t1/2 of 4.78 ± 2.38 h,
a  Cmax  of 3.89 ± 0.83 mg l–1, and a tmax of 0.41 ± 0.19 h. The total body
clearance of mepivacaine is 50% of that of lidocaine, 26.9 ± 10.6 l h–1 vs. 67.9 ± 28.9 l
h–1, respectively (p < 0.0001). (±)Mepivacaine is metabolised into (±)4-OHmepivacaine
(Cmax 0.45 ± 0.25 mg l–1; t1/2b 6.48 ± 6.57 h) and (±)2,6-pipecoloxylidide (Cmax 0.56 ± 0.30
mg l–1; t1/2b 1.48 ± 0.74 h).
For the axillary brachial plexus block, lidocaine and mepivacaine show similar
pharmacodynamic and pharmacokinetic behaviour, despite the number of metabo-
lites, and can therefore be used to the clinical preference for this regional anaes-
thetic technique.
KEY WORDS: lidocaine, mepivacaine, regional analgesia, elimination kinetics, disposition
DOMAINS: pharmaceutical sciences, toxicology, metabolism, drug delivery
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INTRODUCTION
For (short-lasting) surgical procedures on the hand and forearm, intravenous regional anaesthesia
(IVRA)[1] and axillary brachial plexus block are popular techniques[2,3,4].
With the IVRA technique the local anaesthetic drug is administered intravenously in the blood-
less arm, while with the brachial plexus block, the drug is administered into the neurovascular
sheath. If surgery demands analgesia of the whole arm, the local anaesthetic must be administered
around the brachial plexus in the axilla, or even more proximally. When the drug is administered
into the neurovascular sheath, it diffuses into the nerves but also into the adjacent vessels and enters
the systemic circulation[4]. After brachial plexus disposition of the local anaesthetic, a pharmacoki-
netic curve will result, which resembles an oral or intramuscular drug concentration time curve.
This means there must be a clear absorption phase.
Good surgical analgesia is achieved with most local anaesthetic agents, but onset and recovery
will be different. An applied local anaesthetic technique is safe, provided a suitable local anaes-
thetic agent is properly used. Lidocaine and mepivacaine are considered to be suitable agents for
axillary brachial plexus blockade[3,5,6,7,8,9,10,11]. With day case surgery it is considered to be
safe for patients to leave the hospital free of anaesthetic drugs[12,13].
Relatively little has been published on the pharmacokinetics of lidocaine and mepivacaine with
their metabolites when used for axillary brachial plexus anaesthesia. Both compounds are elimi-
nated by hydrolysis of the amide bond and by oxidation. Both compounds form a measurable me-
tabolite in plasma, i.e., (±)4´-hydroxymepivacaine with (±)2,6-pipecoloxylidide (PPX) from
(±)mepivacaine and MEGX (MonoEthylGlycylXylidide) from lidocaine, respectively. The aim of
this investigation is to compare the clinical effect and the pharmacokinetics of lidocaine and
(±)mepivacaine with their metabolites in 2 groups of 15 patients undergoing brachial plexus anaes-
thesia by axillary disposition.
MATERIALS AND METHODS
Patients
The hospital ethics committee of the Medisch Spectrum Twente approved the study, and written
consent to participate was obtained from 15 patients scheduled for hand or forearm surgery (Table 1).
All patients were classified according to the criteria of the American Society of Anesthesiologists as
ASA I or II. Seven men and eight women received mepivacaine. The mean (±s.d.) body weight was
73.5 ± 13.5 kg, body length was 1.74 ± 0.06 m, and age was 49.7 ± 12.3 years.
Ten men and five women received lidocaine. The mean (±s.d.) body weight was 80.4 ± 11.7 kg,
body length was 1.73 ± 0.06 m, and age was 55.5 ± 14.2 years. The study had a double-blind
randomised design.
Patient Preparation
No premedication was given. Two cannulae were introduced into the arm that was not receiving
surgery; one into a suitable vein and the other into the radial artery. The latter was used for continu-
ous monitoring of the arterial blood pressure and for intermittent blood sampling.
Oxygen saturation, pulse rate and EKG, and arterial blood pressure were measured continu-
ously via a Datex “Satlite,” (Datex Division of Instrumentarium Corporation, Helsinki, Finland),
from the first venous cannulation until withdrawal of the final arterial blood sample.
Axillary block was performed with a Stimuplex 50-mm short-bevel needle connected to the
Stimuplex nerve stimulator (B. Braun Melsungen AG, Melsungen, Germany). Using a stimulation
mode of 0.5 mA, 0.3 ms, and 1.0 Hz, perivascular puncture was performed until muscle contrac-
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TABLE 1
Type of Surgery in Both Groups of Patients
Patient No. Lidocaine Surgery Mepivacaine Surgery
1 Dupuytren Tendon suture digit 2
2 Neurome palm of hand Dupuytren
3 Arthroplasty saddle joint Dupuytren
4 Nerve transplantation right arm Tendon suture digit V
5 Dupuytren Dupuytren
6 Nerve transplantation left arm Arthrodese DIP digit III
7 Tenolysis left underarm Correction ulnaris deviation
8 Synovectomy left wrist dorsal Carpal tunnel
9 Dupuytren Arthroscopy right wrist
10 Carpal tunnel Dupuytren
11 Neurolysis N Medianus left wrist Dupuytren
12 Dupuytren Tendon suture digit 2
13 Distal ulnar resection Dupuytren
14 Arthrodese DIP digit V Arthroplasty saddle joint digit 1
15 Dupuytren Plastic saddle joint digit 1
tions indicating stimulation of the median nerve were observed. Over a period of about 30 s, 40 ml
of the local anaesthetic solution were then injected. Concurrently, pressure was applied with the
palpating fingers to the neurovascular sheath just distal to the point of entry of the needle.
Completion of local anaesthetic injection was designated t = 0. Sensory block development was
measured by loss of sensation to pinprick in the cutaneous distributions of the sensory nerves inner-
vating the hand, namely the median nerve, the radial nerve, and the ulnar nerve. Sensory block was
graded according to Hollmén[9] on a three-point rating scale (1 = absence of cold sensation, 2 =
analgesia, 3 = anaesthesia). Sensory block testing commenced at t = 0 and was continued at 2-min
intervals for the first 20 min and at 5-min intervals for the next 20 min. When a sensory block 3 was
not achieved within 40 min, additional systemic analgesics were administered or infiltration with
0.5% bupivacaine in the surgical field was given.
Onset of the surgical analgesia was defined as the period from the end of the injection of the
local anaesthetic to a loss of pinprick sensation (a sensory block 3 score) in the distribution of all
three nerves.
Motor block was assessed by the Baseline Hydraulic Hand Dynamometer (Fabrication Enter-
prises, Inc., Irvington, NY). This device measures the squeeze force, i.e., muscle strength, of the
hand and forearm in either kilograms or pounds. A normal baseline value was established before
commencing the axillary block and designated 100%. The first assessment for motor block was
performed 2 min after the end of the local anaesthetic injection (t = 2) and then repeated at a 2-min
interval for the first 20 min, and at 5-min intervals thereafter in those patients who had not yet
achieved a zero value (100% blockade). The percentage decline in muscle strength from the base
line could then be calculated.
Drugs
Lidocaine (1.5%) (XylocaineÒ, +5 mg l–1 adrenaline ) and mepivacaine (1.5%) (ScandicaineÒ,
+5 mg l–1 adrenaline) were obtained from Astra Pharmaceuticals (Rijswijk, the Netherlands).
Over a period of 30 s, 40 ml of the lidocaine solution (40 ´ 15 mg ml–1 = 600 mg = 2.561 mMol)
were injected around the brachial plexus to each of the patients in the lidocaine group.
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Additionally, 40 ml of the mepivacaine solution (40 ´ 15 mg ml–1 = 600 mg = 2.436 mMol)
were injected around the brachial plexus over a period of 30 s to each of the patients in the mepivacaine
group.
Side Effects
Any skin reactions or subjective complaints were noted.
Sampling
A total of 18 arterial blood samples were taken from each patient. One was drawn immediately
before injection (t = 0) and subsequent samples 5, 10, 15, 20, 25, 30, 40, 50, 60, 75, 90, 105, 120,
135, 150, 165, and 180 min. Blood was collected in tubes containing Li-heparin. The samples were
centrifuged at 3,000 g, and the plasma separated and stored at –20oC until analysis.
Analysis
The plasma concentrations of (±)mepivacaine (C15H22N2O; CAS number 96-88-8; MW 246.35; HCl
salt CAS number 1722-62-9, MW 282.9) with metabolites (±)4´-hydroxymepivacaine (C15H22N2O2)
and (±)2,6-pipecoloxyilidide (PPX) were determined by a modified HPLC method as described
earlier[14]. Briefly, the method is as follows: Column: Spherisorb 5 ODS, 250 ´ 4.6 mm. UV
detection was achieved at 210 nm. Mobile phase: (1 g H3PO4, 0.45 g TMACl in 1 l distilled water)
and acetonitrile (77.5:22.5, v/v) at 1.0 ml min–1 flow rate. Plasma (0.2 ml) was deproteinised with
0.3 ml acetonitrile, vortexed, and centrifuged at 3,000 g. 50 ml was injected onto the column. Reten-
tion times were: 4-OHmepivacaine 5.6 min, PPX 9.6 min, mepivacaine 13.2 min. The limit of
quantification was 0.30 mg ml–1 for both compounds. The inter- and intraday coefficients of vari-
ance for mepivacaine (0.3 –5.0 mg ml–1) and both metabolites (0.3–1.0 mg ml–1) were less than 5%.
The plasma concentration of lidocaine (C14H22N2O; CAS number 137-58-6; MW 234.33; pKa
7.9; HCL.H2O salt CAS number 73-78-9; MW 288.8) and its metabolite MEGX monoethyl-
glycylxylidide (C12H17N2O; MW 220.33) were determined by the same method. The inter- and intraday
coefficients of variance for lidocaine and the metabolite were less than 5%.
Pharmacokinetics
Pharmacokinetic parameters were calculated using a two-compartment model for lidocaine, a one-
compartment model for mepivacaine and its two metabolites, and a noncompartimental analysis
using the MW/Pharm computer package (MediwareR, Groningen, the Netherlands)[15].
Cmax, the maximum plasma concentration (mg l–1) read from the fitted plasma concentration–
time curve (r2 > 0.98); tmax, the time (h) at which Cmax occurred; the elimination half-life associated
with the terminal slope of a semilogarithmic concentration–time curve (ln2/l, [h]), where l = elimi-
nation constant; AUCt, AUC¥, the area under the plasma concentration–time curve (mg h l–1) calcu-
lated (linear trapezoidal method), until the last measured concentration (Ct) or extrapolated to Ct
infinity, respectively; t1/2absorption, the absorption half-life (h); t1/2a, the half-life of the fast elimination
phase, and t1/2b that of the terminal elimination phase; CLt, body clearance is F. Dose/AUCt (assum-
ing F = 1).
CL, total body clearance is F. Dose/AUC¥, assuming the bioavailability F = 1); Vd = F. Dose/Co,
the volume of distribution in the central compartment (F = 1); Vb = CL/b, the volume of distribution
in the second compartment. Vss = F. Dose . AUMC¥/AUC¥2, the volume of distribution at steady
state (F = 1). Mean residence time (MRT) = AUMC¥/AUC¥, where AUMC¥ is the area under the
moment curve from zero to infinity.
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Statistical Analysis
The Mann-Whitney two-tailed test for independent (unpaired) observations was used. Statistical
significance was defined as p < 0.05.
RESULTS
Clinical Response
Onset time of sensory block of the median nerve of both drugs was similar. In 27 patients, satisfac-
tory surgical conditions were reached, as evidenced by good sensory blockade. None of the patients
showed objective symptoms of toxicity, either local or systemic, during and after injection of the
local anaesthetic, nor were there any subjective complaints. Clinically insignificant changes in blood
pressure, heart rate and rhythm, or oxygen saturation were observed at any time during the proce-
dure.
Two patients in the lidocaine group failed to develop sensory block in the distribution of the
radial nerve within an hour after injection. In both individuals infiltration of the surgical area was
necessary with 5 ml bupivacaine 0.5% (Astra). A third patient in the same group failed to develop
any sensory block whatsoever and was given general anaesthesia. The remaining 12 individuals
achieved good surgical anaesthesia without additional systemic analgesics.
Decline in muscle power, expressed as percentage of the preanaesthetic baseline, is plotted vs.
time in Fig. 1A,B. All patients developed a complete motor block within 20 min of injection. Four
patients in the lidocaine group and five patients in the mepivacaine group showed a complete motor
block within 2 min, and one patient in each group needed 20 min to reach the 100% motor block.
The remaining patients reached full blockade in varying periods of time as shown in Fig. 1A,B.
The mean lidocaine motorblock–time-effect curve showed two phases, characterised by a t1/2a
of 0.098 min and a t1/2b of 4.0 min. Mepivacaine showed a similar effect, and the mean motor block-
time effect curves of lidocaine and mepivacaine were similar (p = NS).
Pharmacokinetics
Lidocaine
Figure 2 and Table 2 show the mean plasma concentration–time curves of lidocaine and its metabo-
lite MEGX in 15 patients after axillary administration of the local anaesthetic drug. Lidocaine was
quickly absorbed from the tissues (t1/2abs = 0.14 ± 0.05 h), resulting in a low tmax value of 0.43 ±
0.19 h and a Cmax of 2.87 ± 1.19 mg l–1. The metabolic formation of MEGX by N-dealkylation
started immediately after administration, and the plasma concentration grew in 3 h to 17% of that of
the parent compound. The elimination of lidocaine is biexponential with a short t1/2a of 9.95 ±
14.3 min and a t1/2b of 2.86 ± 1.55 h (Table 3).
The formation and elimination of the metabolite MEGX can be described with a one-compart-
ment model. The apparent t1/2absorption of MEGC (reflecting its rate of formation minus elimination) is
0.70 ± 0.43 h, which is five times longer than that of lidocaine (p < 0.0001). The tmax (2.31 ± 0.84 h)
of MEGX is also five times longer than that of lidocaine (p < 0.0001), while its Cmax is lower (0.32 ±
0.12 mg l–1, p < 0.0001). The elimination half life of MEGX is 2.36 ± 2.35 h and is similar to that of
lidocaine (p = 0.49, Table 4).
Mepivacaine
Figure 3 shows the mean plasma concentration–time curves of mepivacaine and its metabolites 4-
OHmepivacaine and 2,6-pipecoloxylidide (PPX) in 15 patients after axillary administration of the
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FIGURE 1. (A) Individual and mean (n = 12) percentage motorblockade–time curves of lidocaine, after axillary
administration of 600 mg lidocaine (+ 5 mg ml–1 adrenaline). Three patients failed to develop a motor block. (B) Individual
and mean (n = 15) percentage motorblockade–time curves of mepivacaine, after axillary administration of 600 mg
mepivacaine (+ 5 mg ml–1 adrenaline).
FIGURE 1B
FIGURE 1A
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FIGURE 2. Mean plasma concentration–time curves of lidocaine (mg l–1 ± s.d.), its metabolite MEGX after axillary
administration of 600 mg lidocaine (+ 5 mg ml–1 adrenaline) (n = 15).
local anaesthetic drug. Mepivacaine was quickly absorbed from the tissues, resulting in a low tmax
value of 0.41 ± 0.19 h, which was found almost similar to that of lidocaine (p = 0.32), and a Cmax of
3.89 ± 0.83 mg l–1, which was higher than that of lidocaine (p = 0.0157). Mepivacaine is oxidised
into 4´-hydroxymepivacaine, and N-dealkylated into 2,6-pipecoloxylidide (PPX). The elimination
of mepivacaine is monoexponential, with a t1/2b of 4.78 ± 2.38 h.
Table 3 shows the mean values (± s.d.) and statistical differences in the pharmacokinetic param-
eters of lidocaine and mepivacaine. The total body clearance of lidocaine is three times higher than
that of mepivacaine, 67.9 ± 28.9 l h–1 vs. 26.9 ± 10.6 l h–1, respectively (p < 0.0008).
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TABLE 2
Mean Plasma Concentrations (mg l–1 ± s.d.) of Mepivacaine with Metabolite
4-OH and PPX and Lidocaine with its Metabolite MEGX after Axillary
Administration of 40 ml 1.5% = 600 mg (+ 5 mg ml–1 Adrenaline) (n = 15)
Time
(min) Lidocaine MEGX %* Mepivacaine 4-OH PPX
5 1.61 ± 0.82 0.00 ± 0.01 0 2.26 ± 0.58
10 2.22 ± 1.19 0.02 ± 0.03 0.9 3.26 ± 0.91
15 2.63 ± 1.22 0.04 ± 0.05 1.5 3.50 ± 0.77
20 2.74 ± 1.19 0.08 ± 0.08 2.9 3.69 ± 0.84 0.06
25 2.84 ± 1.20 0.12 ± 0.07 4.2 3.79 ± 0.86 0.07
30 2.59 ± 0.92 0.14 ± 0.07 5.4 3.81 ± 0.97 0.22 ± 0.19 0.38
40 2.94 ± 1.12 0.20 ± 0.09 6.8 3.75 ± 0.87 0.32 ± 0.17 0.28 ± 0.10
50 2.72 ± 1.06 0.23 ± 0.11 8.5 4.05 ± 1.07 0.30 ± 0.19 0.33 ± 0.08
60 2.51 ± 1.17 0.25 ± 0.10 10.0 3.62 ± 1.02 0.34 ± 0.18 0.31 ± 0.05
75 2.18 ± 0.85 0.27 ± 0.10 12.4 3.37 ± 1.09 0.39 ± 0.21 0.44 ± 0.10
90 1.94 ± 0.81 0.28 ± 0.10 14.4 3.29 ± 0.94 0.43 ± 0.23 0.53 ± 0.53
105 1.80 ± 0.62 0.28 ± 0.11 15.6 3.10 ± 1.03 0.44 ± 0.24 0.47 ± 0.29
120 1.86 ± 1.15 0.29 ± 0.11 15.6 3.15 ± 1.05 0.51 ± 0.22 0.52 ± 0.33
135 1.77 ± 1.00 0.26 ± 0.07 14.7 2.90 ± 1.07 0.48 ± 0.21 0.53 ± 0.33
150 1.62 ± 0.87 0.27 ± 0.10 16.7 3.00 ± 1.18 0.52 ± 0.24 0.53 ± 0.33
165 1.54 ± 0.89 0.27 ± 0.09 17.5 2.70 ± 1.06 0.45 ± 0.22 0.47 ± 0.07
180 1.44 ± 0.87 0.25 ± 0.08 17.4 2.55 ± 1.02 0.40 ± 0.23 0.51 ± 0.23
%** 15.7 20.0
* Plasma concentration MEGX/lidocaine x 100%. Limit of quantitation 0.02 mg ml–1.
** Plasma concentration metabolite/mepivacaine x 100%.
TABLE 3
Comparison of the Pharmacokinetic Parameters (Mean ± s.d.)
of Lidocaine and Mepivacaine after Axillary Administration of
40 ml 1.5% = 600 mg (+ 5 mg ml–1 Adrenaline) in 15 Patients
Parameter Lidocaine Mepivacaine p
Subjects M/F 10/5 7/8
Body weight kg 80.4 ± 11.7 72.8 ± 13.9 0.12
Age Years 55.5 ± 14.2 49.7 ± 12.3 0.24
Length cm 173.5 ± 64.2 172.5 ± 7.6 0.70
Dose mg 600 600
mMol 2.561 2.436
AUC¥ mg h l –1 10.5 ± 5.24 30.4 ± 22.6 0.0008
AUC3h mg h l –1 5.48 ± 1.71 9.51 ± 2.59 0.0016
Cl¥ l h–1 67.9 ± 28.9 26.9 ± 10.6 0.0008
Cl3h l h–1 120 ± 39.8 66.6 ± 14.4 0.0016
Vd l 92.2 ± 61.2
Vss l 229. ± 70.6
Vß l 241. ± 75.9 150.4 ± 27.12 0.0071
t1/2absorption h 0.14 ± 0.05 0.064 ± 0.035 0.0022
t1/2a min 9.95 ± 14.3
t1/2b h 2.86 ± 1.55 4.78 ± 2.38 0.0106
MRT h 4.02 ± 1.79 7.00 ± 3.45 0.0087
tmax h 0.43 ± 0.19 0.41 ± 0.19 0.3225
Cmax mg l –1 2.87 ± 1.19 3.89 ± 0.83 0.0157
p = Mann-Whitney two-tailed test.
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TABLE 4
Comparison of the Pharmacokinetic Parameters (Mean ± s.d.) of the Lidocaine
and Mepivacaine Metabolites MEGX, 4-OH, and PPX after Axillary
Administration of 40 ml 1.5% = 600 mg (+ 5 mg ml–1 Adrenaline) in 15 Patients
Lidocaine Mepivacaine
Parameter MEGX p PPX p 4-OH p*
Subjects M/F 10/5 7/8
Body weight kg 80.4 ± 11.7 72.8 ± 13.9 0.12
Age Years 55.5 ± 14.2 49.7 ± 12.3 0.24
Length c m 173.5 ± 64.2 172.5 ± 7.6 0.70
Dose mg 600 600
mMol 2.561 2.436
AUC¥ mg h l–1 2.22 ± 1.10 0.22 67.1 ± 88.6 0.045 4.25 ± 2.56 0.73
AUC3h mg h l–1 0.67 ± 0.24 0.22 1.11 ± 0.51 0.045 1.05 ± 0.052 0.74
% AUCparent 13.0 3.89 3.24
t1/2absorption h 0.70 ± 0.43 0.17 1.20 ± 0.87 0.79 0.79 ± 0.75 0.30
t1/2ß h 2.36 ± 2.35 0.73 1.48 ± 0.74 0.0628 6.48 ± 6.57 0.087
MRT h 5.32 ± 3.22 >0.8 4.90 ± 0.17 0.12 10.7 ± 8.90 0.29
tmax h 2.31 ± 0.84 0.0171 3.19 ± 0.28 0.16 1.86 ± 0.50 0.0052
Cmax mg l–1 0.32 ± 0.12 0.0219 0.56 ± 0.30 0.18 0.45 ± 0.25 0.32
p = Mann-Whitney two-tailed test, between MEGX and 4-OH and PPX.
p *= Mann-Whitney two-tailed test, between 4-OH and PPX.
%AUCparent = AUCmetabolite (mMol h l–1; 3 h)/AUC parent (mMol h l–1; 3 h)
The volume of distribution (Vb) of mepivacaine is smaller than that of lidocaine (p = 0.0071),
its Cmax value is higher, 3.89 ± 0.83 vs. 2.87 ± 1.19 mg l–1, resp (p = 0.0157).
Table 4 shows the pharmacokinetic parameters of the metabolites. The tmax and Cmax of the two
xylidide metabolites differed significantly; with PPX the Cmax occurs later, and it is higher than the
Cmax of MEGX.
DISCUSSION
For axillary brachial plexus block a rapid onset of good surgical anaesthesia seems to be important,
but above all the local anaesthetic agent should be safe. (±)Mepivacaine and lidocaine both fulfill
these criteria as reported by several authors[5,7,11,16,17,18]. Eriksson reported that with lidocaine
(450 mg without adrenaline) 6 out of 20 patients showed signs of CNS toxicity about 10–15 min
after axillary administration, i.e., pronounced dizziness and nearly a loss of consciousness in one
patient. Reported onset time for lidocaine was 26.6 ± 4.1 min.[18]. We added adrenaline to slow
absorption and to reduce systemic side effects.
The onset of motor block by lidocaine and mepivacaine with 5 mg ml–1 adrenaline was similar.
Development of motor blockade in the present study showed a wide range of rates and proceeds
apparently independently of the plasma concentration time curve (Fig. 1 A,B and Fig. 4). The end-
point of 100% motor blockade was achieved within 2 min by four patients in the lidocaine group
and by five patients in the mepivacaine group, while in each group one patient needed a full 20 min.
Meanwhile, the local anaesthetic is absorbed and appears in the general circulation.
The absorption of both lidocaine and mepivacaine from the axilla region was relatively fast (tmax
0.43 h, respectively 0.41 h). The maximum plasma concentrations of both lidocaine and mepivacaine
were in agreement with those reported earlier[18,19,20,21,22,23] and stayed well below the toxic
concentrations of 5–10 mg ml–1[24,25,26]. Thereafter, lidocaine was eliminated according a
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FIGURE 3. Mean plasma concentration–time curves of mepivacaine (mg l–1  ± s.d.), and its metabolites 4´-
hydroxymepivacaine (4-OH, open dots) and 2,6-pipecoloxylidide (PPX, open squares) after axillary administration of
600 mg mepivacaine (+ 5 mg ml–1 adrenaline) (n = 15).
biexponential decay with t1/2a of 9.95 ± 14.3 min and a t1/2b of 2.86 ± 1.55 h. Mepivacaine was
eliminated according to a monexponential decay with a t1/2b of 4.78 ± 2.38 h, which differed from
that of lidocaine (p = 0.0106). The pharmacokinetic data shown in Table 3 correspond with those
previously reported[6,7,10,11].
The large %CV in the t1/2a of lidocaine was caused by some exceptionally long t1/2a values. In
the lidocaine group 6 out of 15 patients showed a long t1/2a of 23.9 ± 13.5 min, which differed from
the short values of 0.63 ± 0.71 min (p = 0.0018). Three patients did not develop a sensory block in
all nerves after lidocaine injection; this may be due to poor distribution over the nerves. However,
this lack of sensory block could not be related to the individual plasma concentration-time curves
and pharmacokinetics. The differences in the mepivacaine group were much smaller.
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AUC¥ vs. AUC3h
The difference between the pharmacokinetics of lidocaine and mepivacaine can be attributed solely
to the difference in Cmax and t1/2 values, which affects the AUC¥, and AUCt and thus the calculated
total body clearance. Clearance values were based on CL = F.Dose/AUC3h with the assumption that
F = 1. The clearance values of the metabolite (MEGX, PPX, 4-OH) must be multiplied by the
fraction of the dose that is converted into metabolite. The plasma concentration of both parent
compounds did not reach the limit of quantification at t = 3 h, which makes the difference between
the extrapolated AUC¥ and AUC3h constant. The AUC3h is 52% of the AUC¥ for lidocaine and 31%
for mepivacaine. The AUC3h is required for the calculation of the AUC of the metabolite (MEGX,
PPX, 4-OH) because after 3 h sampling this compound shows a plateau plasma concentration.
Elimination must be visible when a much longer sampling period could have been applied. This was
impossible by the nature of the type of day case surgery and the allotted time by the hospital rules.
Calculated clearance was based on the assumption of 100% bioavailability (F = 1). The total
body clearances based on AUC¥ and AUC3h of lidocaine equaled the maximum average liver blood
flow of 1.5 l min–1 (90 l h–1), while that of mepivacaine was half that of the liver blood flow.
Comparison of Metabolism
The metabolism of lidocaine and mepivacaine proceeds via cytochrome P450 isoenzymes, resulting
in N-hydroxylation, N-dealkylation (MEGX, GX), and the principal reaction of 4-hydroxylation
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FIGURE 4. Mean percentage motor blockade (dots) and mean plasma concentration–time curves (squares) of lidocaine
(solid symbols), and mepivacaine (open symbols) after axillary administration of 600 mg (+ 5 mg ml–1 adrenaline) (n = 15).
Decrease in motor blockade can be tested only before surgery, while testing of the recovery is not possible due to appendages.
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(80% of the dose in urine)[27,28,29,30,31,32,33,34,35,36,37,38]. In this study we were able to
measure the plasma concentration of MEGX, which increased to 17% of the lidocaine plasma con-
centration, and its AUCt was 13% of that of the AUCt of parent drug. The plasma concentrations of
the mepivacaine metabolites increased to 15.7% (4-OHmepivacaine) and 20.0% (PPX) of the con-
centration of the parent drug. The AUCt of the mepivacaine metabolites was 3.89% (PPX) and
3.24% (4-OHmepivacaine) of the AUCt of mepivacaine. Measurement of the metabolite MEGX
was not possible when lidocaine was administered in IVRA at a (low) dose of 200 mg[39].
The enantiomers of (±)mepivacaine show the same pharmacokinetic behaviour, which is also
similar to the pharmacokinetics of the racemate[7,40], while D(–)-mepivacaine is more active than
L(+)-mepivacaine[41,42,43].
CONCLUSION
It can be concluded that both lidocaine and mepivacaine are suitable and safe agents for axillary
brachial plexus block with rapid onset of good surgical analgesia. This is in line with everyday
practice in most institutions. Both compounds are absorbed rapidly from the neurovascular sheath
and eliminated with a short t1/2ß of 2.9 h for lidocaine and 4.8 h for mepivacaine.
Mepivacaine is a racemic mixture, which to date is considered to be not theoretically correct,
however clinically this racemic mixture is effective and nontoxic in the dose applied. Although
there are kinetic differences between the two drugs, they have no clinical consequences.
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